Comparative Pharmacology
Head-to-head clinical analysis: ESTRONE versus NATURAL ESTROGENIC SUBSTANCE ESTRONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTRONE versus NATURAL ESTROGENIC SUBSTANCE ESTRONE.
ESTRONE vs NATURAL ESTROGENIC SUBSTANCE-ESTRONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estrone is a natural estrogen that binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene expression and exerting estrogenic effects on reproductive, skeletal, and cardiovascular systems.
Estrone binds to and activates estrogen receptors (ERα and ERβ), leading to modulation of gene transcription and subsequent estrogenic effects on target tissues.
For menopausal hormone therapy: 0.625-5 mg orally once daily; or 0.1-0.5 mg transdermally once weekly; or 2.5-5 mg intramuscularly every 2-4 weeks.
0.1 to 0.5 mg intramuscularly 2 to 3 times per week for estrogen replacement therapy
None Documented
None Documented
Terminal elimination half-life is 24-36 hours; due to enterohepatic recirculation and slow clearance of conjugates, clinical effects persist for several days after discontinuation.
Clinical Note
moderateEstrone + Gatifloxacin
"The risk or severity of adverse effects can be increased when Estrone is combined with Gatifloxacin."
Clinical Note
moderateEstrone sulfate + Gatifloxacin
"The risk or severity of adverse effects can be increased when Estrone sulfate is combined with Gatifloxacin."
Clinical Note
moderateEstrone + Rosoxacin
"The risk or severity of adverse effects can be increased when Estrone is combined with Rosoxacin."
Clinical Note
moderateEstrone sulfate + Rosoxacin
Terminal half-life: 24-48 hours (prolonged due to enterohepatic recirculation and tissue distribution).
Renal (approximately 60-80% as glucuronide and sulfate conjugates), biliary/fecal (20-40%)
Renal: ~50% (as glucuronide and sulfate conjugates), Biliary/Fecal: ~50% (enterohepatic recirculation).
Category C
Category C
Estrogen
Estrogen
"The risk or severity of adverse effects can be increased when Estrone sulfate is combined with Rosoxacin."